🔗 Share this article

Given that America continues making unprecedented changes to its immunization recommendations, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning coronavirus vaccinations in the pandemic and has zeroed in on potential deaths following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Program

Public health authorities had intended to unveil sweeping revisions to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of step with a large portion of the global community with little proof for improved outcomes. The planned update has been delayed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is set to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and biologics branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has often pushed for halting certain childhood vaccine recommendations in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – typically the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Expertise

Høeg has little discernible experience in drug development, oversight or administrative roles, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a large organization. She is not an expert in industry regulation.”

Previous directors of CBER would “grasp legal statutes and the research of drug development”, commented Janet Woodcock. “Clearly, she lacks the type of experience that former directors who led CBER have had.”

CDER has an enormous workload at the FDA, she pointed out.

“Many people just pays attention on the innovative therapies, but the generic drug division clears a multitude of generic medications. There is also a biologic copycat branch, OTC medication office and more, and all of those have to be looked after,” she said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial administrative component to the job, which manages more than 5,000 personnel. “It is a huge leadership role, if you do it right,” she said.

Response and Controversial Policies

When asked about concerns about Dr. Høeg's credentials and whether this selection represents more teamwork among agency officials on vaccines, a press secretary said that the “questions are based on flawed assumptions”.

“Her experience matches the functions of her role,” the representative stated, noting the period Høeg spent guiding the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s recently launched priority voucher program, a contentious one-day medication authorization process that allegedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, with the exception of immunizations.”

Public Past Work on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, history, some experts said. She released a analysis using unverified crowd-sourced reports to determine the rate of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are riskier than they are.

Among her “wish list” for the new administration included revising guidelines for new vaccines and ending “unnecessary” vaccines, she remarked after the election on a online show. At the agency, Høeg has allegedly suggested excluding teenage boys from getting COVID-19 vaccines.

“She’s an all-around ideologue who commences with her beliefs and works backwards to accommodate the evidence in a extremely misleading, dishonest manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|